Although silibinin has shown chemopreventive and chemosensitizing activity against various human malignancies through multiple molecular pathways [102,103], lung cancer is becoming the paradigm for how the deconstruction of a central mechanism of action of silibinin (i.e., STAT3) has enabled this natural compound to reach clinical development. Here, STAT3 is linked to lung cancer.